Literature DB >> 14695835

Chemical basis for the biological activity of imexon and related cyanoaziridines.

Bhashyam S Iyengar1, Robert T Dorr, William A Remers.   

Abstract

Chemical aspects of mode of action of imexon and related cyanoaziridines were studied. These compounds do not alkylate DNA nor react with the epsilon-amino groups of l-lysine, despite the presence of an aziridine ring. They do react readily with biologically important sulfhydryl compounds to give products derived from either aziridine ring opening, interaction with the cyano group of cyanoaziridines, or opening of the iminopyrrolidone ring of imexon. The products from reactions of imexon and related cyanoaziridines with thiols are not as potent as their parent compounds against tumor cells. These results are consistent with biological studies that show that the mechanism of cytotoxicity involves thiol depletion followed by oxidative stress leading to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695835     DOI: 10.1021/jm030225v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.

Authors:  Elena V Sheveleva; Terry H Landowski; Betty K Samulitis; Geoffrey Bartholomeusz; Garth Powis; Robert T Dorr
Journal:  Mol Cancer Res       Date:  2012-01-24       Impact factor: 5.852

2.  Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.

Authors:  Nicholas O Roman; Betty K Samulitis; Lee Wisner; Terry H Landowski; Robert T Dorr
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-26       Impact factor: 3.333

3.  Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.

Authors:  Robert T Dorr; Lee Wisner; Betty K Samulitis; Terry H Landowski; William A Remers
Journal:  Cancer Chemother Pharmacol       Date:  2011-12-21       Impact factor: 3.333

4.  Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Authors:  Julie Scott; Robert T Dorr; Betty Samulitis; Terry H Landowski
Journal:  Cancer Chemother Pharmacol       Date:  2007-02-28       Impact factor: 3.333

5.  Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.

Authors:  Robert T Dorr; Mary Ann Raymond; Terry H Landowski; Nicholas O Roman; Shoji Fukushima
Journal:  Int J Gastrointest Cancer       Date:  2005

6.  A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.

Authors:  Stacy Moulder; Navneet Dhillon; Chaan Ng; David Hong; Jennifer Wheler; Aung Naing; Susan Tse; Amy La Paglia; Robert Dorr; Evan Hersh; Michelle Boytim; Razelle Kurzrock
Journal:  Invest New Drugs       Date:  2009-06-06       Impact factor: 3.850

Review 7.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

8.  Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium.

Authors:  Gerald P Guntle; Bhumasamudram Jagadish; Eugene A Mash; Garth Powis; Robert T Dorr; Natarajan Raghunand
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

9.  Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.

Authors:  Betty K Samulitis; Terry H Landowski; Robert T Dorr
Journal:  Invest New Drugs       Date:  2008-07-08       Impact factor: 3.850

10.  Bz-423 superoxide signals apoptosis via selective activation of JNK, Bak, and Bax.

Authors:  Neal B Blatt; Anthony E Boitano; Costas A Lyssiotis; Anthony W Opipari; Gary D Glick
Journal:  Free Radic Biol Med       Date:  2008-08-03       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.